Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 44.00, indicating a potential upside of 84.1% from the current price of HKD 23.90 [2][3][10]. Core Insights - The company is expected to achieve profitability again in 2024, driven by strong overseas sales of Furmonertinib and effective cost control measures. The focus for 2025 will be on the NDA submission for SAVANNAH in the U.S. and the progress of new product approvals in mainland China [3][7]. - Despite a decline in one-time collaboration income, the company has managed to maintain a positive outlook due to robust sales performance and cost management [3][7]. - The company’s revenue for 2025 is projected at USD 708 million, with a slight decrease from previous estimates, while net profit is expected to rise significantly to USD 452 million, reflecting a 15% increase from prior forecasts [6][12]. Financial Projections - Revenue and profit forecasts for 2025-2027 show a slight downward adjustment of 1-4% for revenue, but an increase in net profit projections due to ongoing cost control efforts [7][12]. - The company anticipates oncology and immunology revenue to reach USD 350-450 million in 2025, with a projected growth of over 30% in product market sales [7]. - The DCF model estimates the company's equity value at approximately USD 4.916 billion, translating to a per-share value of HKD 44.00 [8][12]. Market Performance - The stock has shown a year-to-date increase of 5.99%, with a 52-week high of HKD 34.70 and a low of HKD 20.25 [5][11]. - The report highlights the significant growth in oncology product revenue, which increased by 65% year-on-year, primarily due to the strong market performance of Furmonertinib [7][12].
和黄医药（00013）：2024年再次实现盈利，SAVANNAH注册队列数据优异，维持买入评级